Despite availability of standardized drug therapies with proven beneficial outcomes, heart failure is associated with poor quality of life, increased hospital readmission, and high mortality rate. In the recent years, comprehensive understanding of the pathophysiological mechanisms of heart failure has led to the development and approval of 2 new pharmacological agents, sacubitril–valsartan and ivabradine. These agents are currently approved for use in heart failure with reduced ejection fraction (HFrEF) and present as novel approaches to further improve prognosis and outcomes in patients with HF. They offer alternative treatment options for patients who are intolerant or continue to be symptomatic despite utilization of standard HF drug therapies at optimally tolerated dosages. A review of these 2 novel agents in HFrEF, including information on pivotal trials that led to its approval and its place in therapy for HFrEF, is presented.
YancyCWJessupMBozkurtB; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2013;62(16):e147–e239.
2.
MozaffarianDBenjaminEJGoAS. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–e322.
3.
BakerDWEinstadterDThomasC. Mortality trends for 23,505 Medicare patients hospitalized with heart failure in Northeast Ohio, 1991 to 1997. Am Heart J. 2003;146(2):258–264.
4.
DharmarajanKHsiehAFLinZ. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309(4):355–363.
5.
LillybladMP.Dual angiotensin receptor and neprilysin inhibition with sacubitril/valsartan in chronic systolic heart failure: understanding the new PARADIGM. Ann Pharmacother. 2015;49(11):1237–1251.
6.
HoustonBAKalathiyaRJKimDA. Volume overload in heart failure: an evidence-based review of strategies for treatment and prevention. Mayo Clin Proc. 2015;90(9):1247–1261.
7.
AlbertNM. Fluid management strategies in heart failure. Critical Care Nurse. 2012;32(2):20–32.
8.
PittBZannadFRemmeWJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717.
9.
PittBRemmeWZannadF. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–1321.
10.
CohnJNJohnsonGZiescheS. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303–310.
11.
TaylorALZiescheSYancyC. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–2057.
12.
TaylorALZiescheSYancyCW. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation. 2007;115(13):1747–1753.
13.
AhmedARichMWLoveTE. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27(2):178–186.
14.
Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–533.
15.
CohnJNTognoniG; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–1675.
16.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316(23):1429–1435.
17.
McMurrayJJVPackerMDesaiAS. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
18.
LeeVCRhewDCDylanM. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med. 2004;141(9):693–704.
19.
GargRYusufS. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450–1456.
20.
ChatterjeeSBiondi-ZoccaiGAbbateA. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346: f55.
21.
KingJBBressAPReeseAD. Neprilysin inhibition in heart failure with reduced ejection fraction: a clinical review. Pharmacotherapy. 2015;35(9):823–837.
WongCYChaudhrySIDesaiMM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124(2):136–143.
24.
OpasichCRapezziCLucciD. Precipitating factors and decision-making processes of short-term worsening heart failure despite “optimal” treatment (from the IN-CHF Registry). Am J Cardiol. 2001;88(4):382–387.
25.
CurtisLHGreinerMAHammillBG. Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med. 2008;168(22):2481–2488.
26.
FonarowGCYancyCWHernandezAF. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J. 2011;161(6):1024–1030.e3.
27.
FonarowGCAlbertNMCurtisAB. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122(6):585–596.
28.
BavishiCMesserliFHKadoshB. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J. 2015;36(30):1967–1973.
29.
von LuederTGSangaralinghamSJWangBH. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail. 2013;6(3):594–605.
30.
HaniganSDiDomenicoRJ. Emerging therapies for acute and chronic heart failure: hope or hype?J Pharm Pract. 2016;29(1):46–57.
31.
Entresto [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation; 2015.
32.
PackerMCaliffRMKonstamMA. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106(8):920–926.
33.
KostisJBPackerMBlackHR. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2):103–111.
34.
RuilopeLMDukatABöhmM. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255–1266.
35.
KarioKSunNChiangFT. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698–705.
36.
SolomonSDZileMPieskeB. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387–1395.
37.
MoeGWEzekowitzJAO’MearaE. The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol. 2015;31(1):3–16.
38.
SarrafMFrancisGS. It is all about heart rate. Or is it?J Am Coll Cardiol. 2012;59(22):1946–1947.
39.
BöhmMSwedbergKKomajdaM. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376(9744):886–894.
40.
ScicchitanoPCarbonaraSRicciG. HCN channels and heart rate. Molecules. 2012;17(12):4225–4235.
41.
CicconeMScicchitanoPCorteseF. Ivabradine, coronary artery disease, and heart failure: beyond rhythm control. Drug Des Devel Ther. 2014;8:689–700.
42.
JessupMBrozenaS. Heart failure. N Engl J Med. 2003;348(20):2007–2018.
43.
KatzAM. The “modern” view of heart failure: how did we get here?Circ Heart Fail. 2008;1(1):63–71.
44.
KingMKingeryJCaseyB. Diagnosis and evaluation of heart failure. Am Fam Physician. 2012;85(12):1161–1168.
45.
NawarskasJJBowmanBNAndersonJR. Ivabradine: a unique and intriguing medication for treating cardiovascular disease. Cardiol Rev. 2015;23(4):201–211.
SwedbergKKomajdaMBöhmM. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–885.
48.
SavelievaICammAJ. Novel If current inhibitor ivabradine: safety considerations. Adv Cardiol. 2006;43:79–96.
49.
PetiteSEBishopBMMauroVF. Role of the funny current inhibitor ivabradine in cardiac pharmacotherapy: a systematic review[published online February 23, 2016].Am J Ther. 2016.
50.
SwedbergKKomajdaMBöhmM; SHIFT Investigators. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59(22):1938–1945.
51.
FoxKFordIStegPG; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807–816.
52.
TeerlinkJR. Ivabradine in heart failure—no paradigm SHIFT…yet. Lancet. 2010;376(9744):847–849.
53.
ChatterjeeSBiondi-ZoccaiGAbbateA. Benefits of blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346:f55.
54.
McMurrayJJAdamopoulosSAnkerSD. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–1847.
55.
Institute for Clinical and Economic Review. CardioMEMS HF System (St Jude Medical) and Sacubitril/Valsartan (Entresto, Novartis) for Management of Congestive Heart Failure: Effectiveness, Value, and Value, Based Price Benchmarks. Boston, MA: Institute for Clinical and Economic Review; 2015.
